Personalized multichannel transcranial direct current electrical stimulation ( <scp>tDCS</scp> ) in drug‐resistant epilepsy: A <scp>SEEG</scp> based open‐labeled study

Auteurs

Bartolomei F, Daoud M, Delourme M, Tardoski S, Makhalova J, Bourguiba E, Medina Villalon S, Lagarde S, Wendling F, Ruffini G, Salvador R, Pizzo F, Giusiano B

Les auteurs en lien sont membres de l'INS.

Équipes

DynaMap

Résumé

Abstract Objective To evaluate the effects of personalized multichannel tDCS on seizure frequency, severity, quality of life, and psychiatric comorbidities in patients with drug‐resistant focal epilepsy. Secondary goals include assessing the safety and feasibility of this approach. Methods This open‐label pilot study involved 16 patients with drug‐resistant focal epilepsy. Patients underwent 3 cycles of personalized multichannel tDCS over 6 months, targeting the EZ defined by stereoelectroencephalography (SEEG). Each cycle consisted of five consecutive days of tDCS, with two daily sessions of 20 min each. The primary endpoint was a reduction in seizure frequency, with secondary endpoints addressing quality of life (QOLIE‐31 scores), seizure severity (NHS3 scores), and psychiatric comorbidities (NDDI‐E and GAD‐7 scales). Results Across all participants, a statistically significant 20% reduction in seizure frequency was observed ( p = 0.044). Six patients (37%) were identified as responders (≥50% seizure reduction), with one achieving seizure freedom. The mean seizure reduction among responders was 68%. Significant improvements were noted in overall quality of life (QOLIE‐31, p = 0.0

Abstract Objective To evaluate the effects of personalized multichannel tDCS on seizure frequency, severity, quality of life, and psychiatric comorbidities in patients with drug‐resistant focal epilepsy. Secondary goals include assessing the safety and feasibility of this approach. Methods This open‐label pilot study involved 16 patients with drug‐resistant focal epilepsy. Patients underwent 3 cycles of personalized multichannel tDCS over 6 months, targeting the EZ defined by stereoelectroencephalography (SEEG). Each cycle consisted of five consecutive days of tDCS, with two daily sessions of 20 min each. The primary endpoint was a reduction in seizure frequency, with secondary endpoints addressing quality of life (QOLIE‐31 scores), seizure severity (NHS3 scores), and psychiatric comorbidities (NDDI‐E and GAD‐7 scales). Results Across all participants, a statistically significant 20% reduction in seizure frequency was observed ( p = 0.044). Six patients (37%) were identified as responders (≥50% seizure reduction), with one achieving seizure freedom. The mean seizure reduction among responders was 68%. Significant improvements were noted in overall quality of life (QOLIE‐31, p = 0.0

Lire l’article